By June Kinoshita, Director of Research and Patient Engagement “Positive benefit/risk supports losmapimod’s potential to be a transformative therapy for the treatment of FSHD”—Fulcrum Therapeutics Fulcrum Therapeutics announced today that… Read More »
This Q&A is based on the December 9 webinar with Rabi Tawil, MD, and Ghinwa Dumyati, MD, from the University of Rochester Medical Center, and the January 15 webinar hosted… Read More »
Growing numbers of companies and academic laboratories are pressing forward with early-stage drug development efforts. This chart shows how far various candidate anti-DUX4 drugs have progressed along the path to… Read More »
Article contributed by Pangenia. About Pangenia Genomics Pangenia is one of the leading diagnostic companies in Hong Kong with 15 years of experience in diagnostics and targeted treatment of hereditary… Read More »
In this presentation, Heloise Hoffmann shares her study focusing on understanding the relationship between FSHD, sleep, and pain. Sleep is essential, but it could be affected by FSHD. To… Read More »
The Walk & Roll to Cure FSHD is the only national event focused solely on funding progress for FSHD. Led entirely by dedicated volunteers, supported by staff, events take place… Read More »
Here are Dr. Nikia Stinson’s slides (ppt) Equipment List (downloadable) All of these are available on Amazon. Com and other online shopping sites.
by Jean Devenport, Melbourne Beach, Florida Like many of you living with muscular dystrophy, I long knew something was wrong, but I was not sure what it was. Most of… Read More »